Overview: Fecal Calprotectin Marker Rapid TestIntroduction: The Fecal Calprotectin Marker Rapid Test is a diagnostic tool designed to detect calprotectin levels in stool samples, facilitating the screening of inflammatory bowel disease (IBD). Associated with conditions like Crohn's disease or ulcerative colitis, this gastrointestinal disorder presents with diarrhea, abdominal pain, and severe complications like colorectal cancer if untreated, particularly in individuals with chronic inflammation. Per the 2023 American Gastroenterological Association guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in gastroenterology settings. This rapid diagnostic falls under clinical pathology and targets individuals with digestive symptoms or IBD risk factors, addressing the challenge of early detection to guide anti-inflammatory therapy or surgery. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its single-sample capability enhances its practicality.Other Names: Calprotectin Rapid Test.FDA Status: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Bühlmann, this test advanced IBD marker detection, providing a rapid alternative to ELISA with a focus on calprotectin.Purpose: The test screens for Fecal Calprotectin to guide IBD diagnosis, assess inflammation status, and inform treatment and prevention strategies.Test Parameters: Presence of Fecal Calprotectin, detected with reasonable specificity to indicate intestinal inflammation, typically detectable in stool at elevated levels during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report diarrhea, abdominal pain, or recent weight loss.Specimen: Stool 5-10 gm, collected using sterile containers, transported within 48 hours to maintain sample viability.Sample Stability at Room Temperature: 48 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on diarrhea, abdominal pain, blood in stool, or prior IBD diagnosis, as well as any family history of gastrointestinal disease or recent infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated IBD including colorectal cancer, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 48 hours, improper storage conditions, cross-contamination with other samples, or recent NSAID use can affect results. Correlation with colonoscopy or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible IBD, necessitating further investigation like colonoscopy or gastroenterology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during remission.Specialist Consultation: Gastroenterologists should be consulted for case management, treatment planning, and coordination with IBD programs.Additional Supporting Tests: Colonoscopy, CRP, or fecal occult blood for confirmation.Test Limitations: The test may produce false positives in infections or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AGA Guidelines 2023, Journal of Gastroenterology 2024, Pathology 2025.